Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2015 1
2016 2
2017 4
2018 3
2019 1
2020 3
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Eph receptors as oncotargets.
Charmsaz S, Boyd AW. Charmsaz S, et al. Oncotarget. 2017 Sep 19;8(47):81727-81728. doi: 10.18632/oncotarget.21045. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137214 Free PMC article. No abstract available.
Innovative Technologies Changing Cancer Treatment.
Charmsaz S, Prencipe M, Kiely M, Pidgeon GP, Collins DM. Charmsaz S, et al. Cancers (Basel). 2018 Jun 19;10(6):208. doi: 10.3390/cancers10060208. Cancers (Basel). 2018. PMID: 29921753 Free PMC article.
ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.
Charmsaz S, Doherty B, Cocchiglia S, Varešlija D, Marino A, Cosgrove N, Marques R, Priedigkeit N, Purcell S, Bane F, Bolger J, Byrne C, O'Halloran PJ, Brett F, Sheehan K, Brennan K, Hopkins AM, Keelan S, Jagust P, Madden S, Martinelli C, Battaglini M, Oesterreich S, Lee AV, Ciofani G, Hill ADK, Young LS. Charmsaz S, et al. BMC Med. 2020 Nov 19;18(1):349. doi: 10.1186/s12916-020-01806-4. BMC Med. 2020. PMID: 33208158 Free PMC article.
Systemic inhibition of PTPN22 augments anticancer immunity.
Ho WJ, Croessmann S, Lin J, Phyo ZH, Charmsaz S, Danilova L, Mohan AA, Gross NE, Chen F, Dong J, Aggarwal D, Bai Y, Wang J, He J, Leatherman JM, Yarchoan M, Armstrong TD, Zaidi N, Fertig EJ, Denny JC, Park BH, Zhang ZY, Jaffee EM. Ho WJ, et al. Among authors: charmsaz s. J Clin Invest. 2021 Jul 20:146950. doi: 10.1172/JCI146950. Online ahead of print. J Clin Invest. 2021. PMID: 34283806 Free article.
Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype.
Varešlija D, Ward E, Purcell SP, Cosgrove NS, Cocchiglia S, O'Halloran PJ, Charmsaz S, Bane FT, Brett FM, Farrell M, Cryan J, Beausang A, Hudson L, Turnbul AK, Dixon JM, Hill ADK, Priedigkeit N, Oesterreich S, Lee AV, Sims AH, Redmond AM, Carroll JS, Young LS. Varešlija D, et al. Among authors: charmsaz s. Oncogene. 2021 Feb;40(7):1318-1331. doi: 10.1038/s41388-020-01606-3. Epub 2021 Jan 8. Oncogene. 2021. PMID: 33420368 Free PMC article.
S100β as a serum marker in endocrine resistant breast cancer.
Charmsaz S, Hughes É, Bane FT, Tibbitts P, McIlroy M, Byrne C, Cocchiglia S, McBryan J, Hennessy BT, Dwyer RM, Kerin MJ, Hill AD, Young LS. Charmsaz S, et al. BMC Med. 2017 Apr 12;15(1):79. doi: 10.1186/s12916-017-0836-2. BMC Med. 2017. PMID: 28399921 Free PMC article. Clinical Trial.
20 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page